Search Results
189 results found-
CSL Seqirus provides innovative solutions for pandemic preparedness and response.
https://www.csl.com/patients-public-health/vaccines/pandemic-response -
CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
CSL is committed to pricing practices that reflect the value our products bring to patients and society.
https://www.csl.com/sustainability/social/access-and-health-security -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
on Monday, September 26, 2022, from 11:30-12:30 BST, highlighting the importance of influenza pandemic preparedness, the role of neuraminidase in influenza infection and the value of real-world evidence in public health decision making.
https://newsroom.csl.com/2022-09-13-CSL-Seqirus-to-Highlight-Commitment-to-Influenza-Protection-with-More-than-20-Data-Presentations-at-OPTIONS-XI -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
We are a diverse collective of people after one goal - to reimagine, reinvent and find new answers that save, improve and protect life.
https://www.csl.com/we-are-csl -
CSL's is recognized for our contributions to developing breakthrough medicines that have the potential to help millions of patients worldwide.
https://www.csl.com/research-and-development/r-and-d-capabilities -
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
https://newsroom.csl.com/2022-10-05-CSL-Announces-Positive-Preclinical-Data-for-Self-Amplifying-Messenger-RNA-sa-mRNA-Influenza-Vaccine-Candidates -
Collaboration and license agreement with Arcturus Therapeutics aims to accelerate next-generation mRNA capabilities in influenza, pandemic preparedness and other selected respiratory viral pathogens -- including a near term COVID-19 vaccine that has recently reported interim results from a large Phase III efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favourable safety profile.
https://newsroom.csl.com/2022-11-02-Next-Generation-mRNA,-Gene-Therapy,-Plasma-Products,-Monoclonal-Antibodies,-and-Recent-Acquisitions-and-Collaborations-Highlight-CSL-R-D-Day-2022